• Home
  • Clinical Trials
  • A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) following first-line induction therapy with carboplatin, etoposide and atezolizumab

    Print Print

    Share this page

    Close Tooltip
    Copy Link Tooltip

    Copy page URL

    Trial Status:


    Location

    Trial Runs In:

    Folder

    The below information is taken directly from public registry websites such as ClinicalTrials.gov,  EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

    Trial Summary

    Download resource Download

    Trial Id

    Eligibility Criteria

    Clinical Trial ResultsClose Tooltip

    Welcome to Medically

    The Roche Science Hub

    This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.

    Not a healthcare professional? Browse:

    This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

    You are Leaving Medically

    By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

    You are Leaving the Global Medically Site

    By following this link, you are being redirected to another Roche page.